The Cancer Genome Atlas (TCGA) is a comprehensive program investigating the molecular basis of cancer through the application of genome analysis technologies. TCGA is a joint effort of the National Cancer Institute (NCI), the National Human Genome Research Institute (NHGRI), and multiple clinical centers participating in the specimens and clinical data collection.

Since 2010, Cureline, Inc. is a trusted partner of The Cancer Genome Atlas (TCGA) program dedicated to deciphering the human cancer genomes. Cureline team has excelled in providing specimens and clinical data for complex molecular DNA and RNA analyses by the program participants in a variety of indications including breast cancer, lung cancer (adenocarcinoma and SCC), renal cancer, endometrial cancer, gastric carcinoma, melanoma, brain cancers, pancreatic cancer, soft tissue sarcoma, and esophageal carcinoma among others.

The tumor tissue samples and normal control specimens collected from the same patients have been undergoing the rigorous quality control at the participating clinical sites, Cureline Tissue Bank and TCGA tissue processing and analysis centers. TCGA has taken great strides to ensure that the tissues studied are of the highest quality, and Cureline team has been prized many times for the samples provided.

The genetic data are now available for the public use from the TCGA consortium, and we provide specific samples that have been collected for this program to our clients (FF tumor, FFPE tumor, serum, plasma) for the additional analyses.